Publications

Publications 2019 – Partner 8

  • Editorial: Ankylosing Spondylitis and Related Immune-Mediated Disorders. https://www.ncbi.nlm.nih.gov/pubmed/31214188?dopt=Abstract Icon for Frontiers Media SA Icon for PubMed Central Related Articles

    Editorial: Ankylosing Spondylitis and Related Immune-Mediated Disorders.

    Front Immunol. 2019;10:1232

    Authors: Fiorillo MT, Haroon N, Ciccia F, Breban M

    PMID: 31214188 [PubMed - in process]

  • Tolerogenic XCR1+ dendritic cell population is dysregulated in HLA-B27 transgenic rat model of spondyloarthritis. https://www.ncbi.nlm.nih.gov/pubmed/30717755?dopt=Abstract Icon for BioMed Central Icon for PubMed Central Related Articles

    Tolerogenic XCR1+ dendritic cell population is dysregulated in HLA-B27 transgenic rat model of spondyloarthritis.

    Arthritis Res Ther. 2019 Feb 04;21(1):46

    Authors: Ermoza K, Glatigny S, Jah N, Camilo V, Mambu Mambueni H, Araujo LM, Chiocchia G, Breban M

    Abstract
    BACKGROUND: Spondyloarthritis (SpA) is a chronic inflammatory disease affecting primarily axial and peripheral joints and sometimes also extra-articular organs, such as the gut. Rats transgenic for HLA-B27 and human β2-microglobulin (B27-Tg rat) develop clinical manifestations resembling human disease. In this model, it has been shown that CD103+ conventional dendritic cells (cDCs) exhibited altered functions, likely promoting SpA development. CD4- cDC subpopulation expressing XCR1, a chemokine receptor involved in their migration, have been described to be tolerogenic in steady state. Thus, in this study, we wished to examine the fate of XCR1+ cDCs in this animal model of SpA.
    METHODS: cDC populations were isolated from the spleen, mesenteric lymph nodes (MLN), and colonic lamina propria from B27-TG and control nontransgenic (NTG) and/or HLA-B7 transgenic rats after collagenase digestion and density gradient and characterized with flow cytometry or real-time PCR. Migration of cDCs from intestinal mucosa to MLN was assessed, using TLR-7 stimulation with Resiquimod.
    RESULTS: We observed a reduced frequency of cCD4- DCs in B27-Tg rats, as compared to control rats. Furthermore, such decrease was not due to excessive death of CD4- cDCs in B27-Tg rats. Interestingly, we observed a decrease frequency of the XCR1+ subpopulation among CD4- cDCs in the spleen, MLN, and lamina propria from B27-Tg rats. Finally, after TLR-7 stimulation, the migration of XCR1+ cDCs to MLN was proportionally reduced in B27-Tg rats.
    CONCLUSION: Our results demonstrate for the first time a decreased proportion of the tolerogenic XCR1+ cDC subpopulation in SpA target organs in B27-Tg rat, which may affect the maintenance of self-tolerance and control of inflammation.

    PMID: 30717755 [PubMed - in process]

  • Burden of severe spondyloarthritis in France: A nationwide assessment of prevalence, associated comorbidities and cost. https://www.ncbi.nlm.nih.gov/pubmed/29709699?dopt=Abstract Icon for Elsevier Science Related Articles

    Burden of severe spondyloarthritis in France: A nationwide assessment of prevalence, associated comorbidities and cost.

    Joint Bone Spine. 2019 01;86(1):69-75

    Authors: Claudepierre P, Fagnani F, Cukierman G, de Chalus T, Joubert JM, Laurendeau C, Gourmelen J, Breban M

    Abstract
    OBJECTIVES: To estimate the number of patients with severe spondyloarthritis (SpA) in France, describe their comorbidities and document and value their healthcare resource consumption.
    METHODS: Data were retrieved from an insurance claims database covering a 1/97 random sample of the French population. All patients benefiting from full insurance coverage ("ALD") for severe SpA in 2012 (including cases with structural damage and/or frequent flares) were identified, together with a control group frequency-matched by age and gender. Severe comorbidities were documented through ALD categories. Healthcare resource consumption was documented and valued from the payer's perspective. Rates of comorbidities and costs were compared in SpA patients versus controls using non-parametric testing.
    RESULTS: Overall, 827 patients with ALD status for severe SpA were identified (control group: n=2.481), corresponding to a prevalence rate of 0.18% [0.17-0.19] for SpA with ALD in the general population. Severe comorbidities more frequent in patients with SpA than in controls included inflammatory bowel disorders (odds ratio: 15.0 [6.2-36.2]), hypertension (2.5 [1.6-3.9]), atrial fibrillation (4.3 [1.9-9.6]) and major depressive disorder (2.1 [1.3-3.6]). Mean per capita annual direct healthcare expenditure was 3.6 [3.2-4.1]-fold higher in SpA patients (€6,122 [€5,838-€6,406]) than in controls (€1,682 [€1,566-€1,798]). Extrapolating to all patients in France, total healthcare cost attributable to severe SpA patients was €391 [€355-€426] million, with medication accounting for 53.8% of this cost.
    CONCLUSIONS: The burden of severe SpA in France is substantial, due to the high prevalence, high direct costs and associated comorbidities.

    PMID: 29709699 [PubMed - in process]

  • à LIRE AUSSI...





























































































    Copyright 2015 - INFLAMEX - Création La nageuse